https://www.selleckchem.com/products/ym201636.html
tium type 2 or higher bleeding at 30 days compared with placebo 5.0%, 5.9%, and 8.6% in the revacept, 160 mg, revacept, 80 mg, and placebo groups, respectively (P = .36). Revacept did not reduce myocardial injury in patients with stable ischemic heart disease undergoing percutaneous coronary intervention. There were few bleeding events and no significant differences between treatment arms. ClinicalTrials.gov Identifier NCT03312855. ClinicalTrials.gov Identifier NCT03312855. If family caregivers participate with people with dementia in
Like
Comment
Share
